{"id":"W4200542010","doi":"10.1182/blood-2021-149840","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemtuzumab ozogamicin; Calicheamicin; Cytarabine; Internal medicine; Daunorubicin; Gastroenterology; Refractory (planetary science); Myeloid leukemia; Population; Oncology; CD33; Leukemia; Pharmacology; Stem cell","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007233983,0.0005080979,0.0008877926,0.0003292814,0.0001848642,0.0005453806,0.0003964061,0.0004573672,0.00149148],"category_scores_gemma":[0.0004622683,0.0002519798,0.0005380543,0.0003353086,0.0004550857,0.0004425369,0.0002630243,0.0012781,0.0003266749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000605726,"about_ca_system_score_gemma":0.0006058516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009731236,"about_ca_topic_score_gemma":0.0025135,"domain_scores_codex":[0.9997275,0.000126828,0.00002528483,0.0000430125,0.00003328589,0.00004402953],"domain_scores_gemma":[0.9997756,0.00004466763,0.00006336477,0.00001750282,0.00001083928,0.00008799441],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5470621,0.05461356,0.01568259,0.00159637,0.002888023,0.0004610686,0.0005972885,0.005197371,0.1376963,0.0003658099,0.002674125,0.2311654],"study_design_scores_gemma":[0.1946222,0.7392973,0.0392187,0.00008248202,0.001611248,0.0005646281,0.0001190138,0.002278151,0.01830421,0.0001082766,0.003753703,0.00004009921],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978805,0.00115445,0.0001150273,0.00007344349,0.00001880803,0.0002230783,0.0001683505,0.00002325168,0.0003431799],"genre_scores_gemma":[0.9978158,0.0008204509,0.0002984632,0.00009157736,0.00003393935,0.0001735731,0.0003654481,0.000004926117,0.000395814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00149148,"threshold_uncertainty_score":0.004989505,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006850245217308914,"score_gpt":0.2292275328428613,"score_spread":0.2223772876255524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}